X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement grants Pierre Fabre the worldwide exclusive rights to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax®-ABL library owned by Y-Biologics.
Lead Product(s): Human Antibody-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 06, 2021
Details:
3D Medicines will obtain rights to develop, manufacture, and commercialize YBL-013, a T cell bi-specific engager based on ALiCE platform technology, in the Territory of Greater China (mainland China, Hong Kong, Macau and Taiwan) and will co-developed it across the globe.
Lead Product(s): YBL-013,Envafolimab
Therapeutic Area: Oncology Product Name: YBL-013
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: 3D Medicines
Deal Size: $87.0 million Upfront Cash: $2.0 million
Deal Type: Licensing Agreement January 05, 2021
Details:
Under the terms of this agreement, Y-Biologics will contribute through its human antibody display platforms to generate therapeutic and diagnostic monoclonal antibodies directed against key molecular targets designated by Pierre Fabre.
Lead Product(s): Monoclonal antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
